Thonzonium bromide inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo.
about
Sitagliptin, An Anti-diabetic Drug, Suppresses Estrogen Deficiency-Induced OsteoporosisIn Vivo and Inhibits RANKL-Induced Osteoclast Formation and Bone Resorption In Vitro.The Beneficial Effect of Praeruptorin C on Osteoporotic Bone in Ovariectomized Mice via Suppression of Osteoclast Formation and Bone Resorption.Mandibular Gorham-Stout disease: A case report and literature review.Discovery of antimicrobial compounds targeting bacterial type FAD synthetases.A study on the prevention and treatment of murine calvarial inflammatory osteolysis induced by ultra-high-molecular-weight polyethylene particles with neomangiferin
P2860
Thonzonium bromide inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Thonzonium bromide inhibits RA ...... LPS-induced bone loss in vivo.
@en
type
label
Thonzonium bromide inhibits RA ...... LPS-induced bone loss in vivo.
@en
prefLabel
Thonzonium bromide inhibits RA ...... LPS-induced bone loss in vivo.
@en
P2093
P1476
Thonzonium bromide inhibits RA ...... LPS-induced bone loss in vivo
@en
P2093
Euphemie Landao-Bassonga
James H Steer
Ming H Zheng
P304
P356
10.1016/J.BCP.2016.02.013
P407
P577
2016-02-21T00:00:00Z